These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20553285)

  • 1. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
    N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
    Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
    Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
    Ooba N; Yamaguchi T; Kubota K
    Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT
    Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
    [No Abstract]   [Full Text] [Related]  

  • 10. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB; Reimold SC; O'Suilleabhain PE
    Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiac valvulopathy and dopamine agonist].
    Grandas F
    Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
    Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
    Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
    Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
    Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 17. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
    Tran T; Brophy JM; Suissa S; Renoux C
    CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
    Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
    J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study.
    Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
    J Heart Valve Dis; 2009 Jul; 18(4):463-9. PubMed ID: 19852154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
    Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
    Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.